Merozolyn 5 mgMerozolyn 5 mg is indicated for the treatment of salt and water retention including:
Edema accompanying congestive heart failure
Edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function.
Merozolyn 5 mg is also indicated ... Read moreMerozolyn 5 mg is indicated for the treatment of salt and water retention including:
Edema accompanying congestive heart failure
Edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function.
Merozolyn 5 mg is also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class.Theropeutic ClassThiazide diuretics & related drugsPharmacologyMerozolyn 5 mg is a thiazide-like diuretic. It inhibits reabsorption of sodium in the distal tubules resulting in increased excretion of sodium and water, as well as potassium and hydrogen ions.Dosage & Administration of Merozolyn 5 mgEffective dosage of Merozolyn 5 mg tablets should be individualized according to indication and patient response. A single daily dose is recommended. Therapy with Merozolyn 5 mg tablets should be titrated to gain an initial therapeutic response and to determine the minimal dose possible to maintain the desired therapeutic response.Usual Single Daily Dosage Schedules: Suitable initial dosages will usually fall in the ranges given.Edema of Cardiac Failure: Merozolyn 5 mg tablets 5 to 20 mg once daily.Edema of Renal Disease: Merozolyn 5 mg tablets 5 to 20 mg once daily.Mild to Moderate Essential Hypertension: Merozolyn 5 mg tablets 2.5 to 5 mg once daily.New patients- If considered desirable to switch patients currently on Zaroxolyn tablets and other formulations of Merozolyn 5 mg that share its slow and incomplete bioavailability to Mykrox , the dose should be determined by titration starting at one tablet (0.5 mg) once daily and increasing to two tablets (1 mg) once daily if needed.Treatment Of Edematous States: The time interval required for the initial dosage to produce an effect may vary.?Diuresis?and saluresis usually begin within one hour and persist for 24 hours or longer. When a desired therapeutic effect has been obtained, it may be advisable to reduce the dose if possible. The daily dose depends on the severity of the patient's condition, sodium intake, and responsiveness. A decision to change the daily dose should be based on the results of thorough clinical and laboratory evaluations. If antihypertensive drugs or diuretics are given concurrently with Merozolyn 5 mg tablets, more careful dosage adjustment may be necessary. For patients who tend to experience paroxysmal nocturnal?dyspnea, it may be advisable to employ a larger dose to ensure prolongation of diuresis and saluresis for a full 24-hour period.Treatment Of Hypertension: The time interval required for the initial dosage regimen to show effect may vary from three or four days to three to six weeks in the treatment of elevated blood pressure. Doses should be adjusted at appropriate intervals to achieve maximum therapeutic effect.Dosage of Merozolyn 5 mgEffective dosage of Merozolyn 5 mg tablets should be individualized according to indication and patient response. A single daily dose is recommended. Therapy with Merozolyn 5 mg tablets should be titrated to gain an initial therapeutic response and to determine the minimal dose possible to maintain the desired therapeutic response.Usual Single Daily Dosage Schedules: Suitable initial dosages will usually fall in the ranges given.Edema of Cardiac Failure: Merozolyn 5 mg tablets 5 to 20 mg once daily.Edema of Renal Disease: Merozolyn 5 mg tablets 5 to 20 mg once daily.Mild to Moderate Essential Hypertension: Merozolyn 5 mg tablets 2.5 to 5 mg once daily.New patients- If considered desirable to switch patients currently on Zaroxolyn tablets and other formulations of Merozolyn 5 mg that share its slow and incomplete bioavailability to Mykrox , the dose should be determined by titration starting at one tablet (0.5 mg) once daily and increasing to two tablets (1 mg) once daily if needed.Treatment Of Edematous States: The time interval required for the initial dosage to produce an effect may vary.?Diuresis?and saluresis usually begin within one hour and persist for 24 hours or longer. When a desired therapeutic effect has been obtained, it may be advisable to reduce the dose if possible. The daily dose depends on the severity of the patient's condition, sodium intake, and responsiveness. A decision to change the daily dose should be based on the results of thorough clinical and laboratory evaluations. If antihypertensive drugs or diuretics are given concurrently with Merozolyn 5 mg tablets, more careful dosage adjustment may be necessary. For patients who tend to experience paroxysmal nocturnal?dyspnea, it may be advisable to employ a larger dose to ensure prolongation of diuresis and saluresis for a full 24-hour period.Treatment Of Hypertension: The time interval required for the initial dosage regimen to show effect may vary from three or four days to three to six weeks in the treatment of elevated blood pressure. Doses should be adjusted at appropriate intervals to achieve maximum therapeutic effect.Interaction of Merozolyn 5 mgHypotensive and nephrotoxic effects of ACE inhibitors may be enhanced. Absorption may be reduced with bile acid sequestrants. Hyperglycaemic effect may be enhanced with diazoxide. May increase serum concentration and QTc-prolonging effect of dofetilide. May reduce lithium excretion. Hypotensive effect may be increased with alcohol.ContraindicationsAnuria; hepatic coma or pre-coma. Pregnancy.Side Effects of Merozolyn 5 mgChest pain, palpitation, necrotising angiitis, orthostatic hypotension, syncope, venous thrombosis, vertigo, volume depletion; depression, dizziness, chills, drowsiness, fatigue, restlessness, headache, lightheadedness; petechiae, photosensitivity, hypersensitivity reactions; gout attacks, electrolyte disturbances; abdominal bloating, diarrhoea, abdominal pain, anorexia, constipation, epigastric distress, nausea, xerostomia, pancreatitis, vomiting; impotence; aplastic anaemia, thrombocytopenia, haemoconcentration, leukopenia; cholestatic jaundice, hepatitis; joint pain, muscle cramps, weakness, neuropathy, paraesthesia; blurred vision; increased BUN, glucosuria.Pregnancy & LactationPregnancy?Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).If used in gestational HTN: Pregnancy?Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).Precautions & WarningsPre-diabetes or DM; gout; SLE; hepatic and renal impairment; hypercholesterolaemia. Correct electrolyte disturbances prior to therapy. Risk of cross-sensitivity with sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides and loop diuretics. Lactation.Overdose Effects of Merozolyn 5 mgSymptoms: Orthostatic hypotension, dizziness, drowsiness, syncope, haemoconcentration and haemodynamic changes due to plasma volume depletion. Management: Symptomatic and supportive.Drug ClassesThiazide diuretics & related drugsMode Of ActionMerozolyn 5 mg is a thiazide-like diuretic. It inhibits reabsorption of sodium in the distal tubules resulting in increased excretion of sodium and water, as well as potassium and hydrogen ions.PregnancyPregnancy?Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).If used in gestational HTN: Pregnancy?Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).
₦13,750.00 Original price was: ₦13,750.00.₦12,375.00Current price is: ₦12,375.00.
Merotrax 1 gm/vialMeropenem is indicated for treatment in adults and children for the following infections caused by single or multiple bacteria sensitive to Meropenem. Pneumonia and Nosocomial Pneumonia Urinary Tract Infections Intra-abdominal Infections Gynaecological Infections, such as endometritis and pelvic inflammatory disease ... Read moreMeropenem is indicated for treatment in adults and children for the following infections caused by single or multiple bacteria sensitive to Meropenem. Pneumonia and Nosocomial Pneumonia Urinary Tract Infections Intra-abdominal Infections Gynaecological Infections, such as endometritis and pelvic inflammatory disease Skin and Skin Structure Infections Meningitis Septicaemia Pulmonary infections in cystic fibrosis Empiric treatment for presumed infections in patients with febrile neutropenia. Theropeutic ClassOther beta-lactam AntibioticsPharmacologyMeropenem is a carbapenem antibiotic for parenteral use . It exerts its bactericidal action by interfering with bacterial cell wall synthesis. It penetrates bacterial cell walls, its high level of stability to all serine beta-lactamases and its marked affinity for the Penicillin Binding Proteins (PBPs.). It shows potent bactericidal activity against a broad spectrum of Gram-positive and Gram-negative, aerobic and anaerobic bacteria.Dosage of Merotrax 1 gm/vialThe dosage and duration of therapy shall be established depending on type, severity of infection and the condition of the patient. The recommended daily dosage is as follows-Adults: The usual dose is 500 mg to 1 gm by intravenous administration every 8 hours. Pneumonia, urinary tract infections, gynaecological infections such as endometritis, pelvic inflammatory disease, skin and skin structure infections: 500 mg IV every 8 hours. Nosocomial pneumonias, peritonitis, presumed infections in neutropenic patients and septicaemia: 1 g IV every 8 hours. Intra-abdominal infections: 500 mg to 1 gm every 8 hours. Cystic fibrosis: Upto 2 gm every 8 hours. Meningitis: 2 gm IV every 8 hours. Children: 3 months to 12 years: 10 to 40 mg/kg intravenously every 8 hours depending on type and severity of infection, susceptibility of the pathogens and the condition of the patient. Intra-abdominal infections: 20 mg/kg every 8 hours. Cystic fibrosis (4-18 years): 25-40 mg/kg every 8 hours. Meningitis: 40 mg/kg IV every 8 hours. Febrile neutropenia: 20 mg/kg every 8 hours. Children over 50 kg weight: use adult dosage. There is no experience in children with hepatic or renal impairment. Administration of Merotrax 1 gm/vialMeropenem should be administered by intravenous Infusion over approximately 15-30 minutes or as intravenous bolus (5 to 20 ml) over approximately 3-5 minutesInteraction of Merotrax 1 gm/vialProbenecid competes with Meropenem for active tubular secretion and thus inhibits the renal excretion, with the effect of increasing the elimination half-life and plasma concentration of meropenem. Meropenem may reduce serum valproic acid levels. Sub therapeutic levels may be reached in some patients.ContraindicationsMeropenem is contraindicated in patients who have demonstrated hypersensitivity to this product.Side Effects of Merotrax 1 gm/vialMeropenem is generally well tolerated. Side effects like inflammation, thrombophlebitis, pain at the site of injection, skin reactions like rash, pruritus, urticaria, abdominal pain, nausea, vomiting, diarrhea, headache may occur.Pregnancy & LactationPregnancy Category B. There are no adequate and well-controlled studies in pregnant women. So this drug should be used during pregnancy only if clearly needed. Because many drugs are excreted in human milk, caution should be exercised when Meropenem is administered to a nursing woman.Precautions & WarningsIf an allergic reaction to Meropenem occurs, the drug should be discontinued and appropriate measures taken. Use of Meropenem in patients with hepatic disease should be made with careful monitoring of transaminase and bilirubin levels.Overdose Effects of Merotrax 1 gm/vialAccidental overdose could occur during therapy, particularly in patients with renal impairment. Treatment of overdose should be symptomatic. In normal individuals, rapid renal elimination will occur; in subjects with renal impairment, haemodialysis will remove Meropenem and its metabolite.Storage ConditionsVial store in a cool, dry place (below 30oC), away from light & moisture. Keep out of the reach of children.Use In Special PopulationsRenal impairment: Dosage should be reduced in patients with creatinine clearance less than 51 ml/min.Hepatic impairment: No dosage adjustments are necessary with impairment of liver function. Hemodialysis patients should receive Meropenem after dialysis has been completed.Elderly: No dosage adjustments are necessary in elderly patients unless creatinine clearance is <51 ml/min.Use in Children: Efficacy and tolerability in infants under 3 months have not been established.ReconstitutionPreparation of solution:Intravenous bolus Administration: Reconstitute Meropenem (500 mg or 1 g) with sterile water for injection. Shake to dissolve and to obtain solution which is clear and colorless or pale yellow.Intravenous infusion administration: Meropenem for intravenous infusion may be directly constituted with a compatible infusion fluid and then further diluted (50 to 200 ml) with the compatible infusion fluid, as needed.Meropenem is compatible with the following infusion fluids: 0.9% sodium chloride intravenous infusion, 5% or 10% glucose intravenous infusion, 5% glucose intravenous infusion with 0.02% sodium bicarbonate, 5% glucose and 0.9% sodium chloride intravenous infusion, 5% glucose with 0.225% sodium chloride intravenous infusion, 5% glucose with 0.15% potassium chloride intravenous infusion, 2.5% and 10% mannitol intravenous infusion, normosol-M in 5% glucose intravenous infusion.The use of freshly reconstituted solution is recommended. However, it maintains potency for up to 3 hours at up to 25oC or 13 hours at up to 5oCDrug ClassesOther beta-lactam AntibioticsMode Of ActionMeropenem is a carbapenem antibiotic for parenteral use . It exerts its bactericidal action by interfering with bacterial cell wall synthesis. It penetrates bacterial cell walls, its high level of stability to all serine beta-lactamases and its marked affinity for the Penicillin Binding Proteins (PBPs.). It shows potent bactericidal activity against a broad spectrum of Gram-positive and Gram-negative, aerobic and anaerobic bacteria.PregnancyPregnancy Category B. There are no adequate and well-controlled studies in pregnant women. So this drug should be used during pregnancy only if clearly needed. Because many drugs are excreted in human milk, caution should be exercised when Meropenem is administered to a nursing woman.Pediatric UsesRenal impairment: Dosage should be reduced in patients with creatinine clearance less than 51 ml/min.Hepatic impairment: No dosage adjustments are necessary with impairment of liver function. Hemodialysis patients should receive Meropenem after dialysis has been completed.Elderly: No dosage adjustments are necessary in elderly patients unless creatinine clearance is <51 ml/min.Use in Children: Efficacy and tolerability in infants under 3 months have not been established.![MERRY CHRISTMAS GIFTBAG [SMALLEST]](https://allschoolabs.com/wp-content/uploads/2024/04/CHRISTMAS20WISHES20GIFTBAG205BMEDIUM5D.jpg)
